Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Mar;74(3):294–298. doi: 10.1136/jnnp.74.3.294

[123I]ß-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease

A Winogrodzka 1, P Bergmans 1, J Booij 1, E A van Royen 1, J Stoof 1, E Wolters 1
PMCID: PMC1738309  PMID: 12588911

Abstract

Objectives:To examine the validity of [123I]ß-CIT SPECT for monitoring the progression of dopaminergic degeneration in Parkinson's disease; to investigate the influence of short term treatment with D2receptor agonists on striatal [123I]ß-CIT binding; and to determine the sample size and frequency of SPECT imaging required to demonstrate a significant effect of a putative neuroprotective agent.

Methods:A group of 50 early stage Parkinson's disease patients was examined. Two SPECT imaging series were obtained, 12 months apart. The mean annual change in the ratio of specific to non-specific [123I]ß-CIT binding to the striatum, putamen, and caudate nucleus was used as the outcome measure.

Results:A decrease in [123I]ß-CIT binding ratios between the two images was found in all regions of interest. The average decrease in [123I]ß-CIT binding ratios was about 8% in the whole striatum, 8% in the putaminal region, and 4% in the caudate region. Comparison of scans done in nine patients under two different conditions—in the off state and while on drug treatment—showed no significant alterations in the expression of striatal dopamine transporters as measured using [123I]ß-CIT SPECT. Power analysis indicated that to detect a significant (p < 0.05) effect of a neuroprotective agent with 0.80 power and 30% of predicted protection within two years, 216 patients are required in each group when the effects are measured in the whole putamen.

Conclusions:[123I]ß-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in Parkinson's disease and may provide an objective method of measuring the effectiveness of neuroprotective treatments. Short term treatment with a D2agonist does not have a significant influence on [123I]ß-CIT binding to dopamine transporters. If the latter finding is replicated in larger groups of patients, it supports the suitability of [123I]ß-CIT SPECT for examining the progression of neurodegeneration in patients being treated with D2receptor agonists.

Full Text

The Full Text of this article is available as a PDF (141.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlskog J. E., Uitti R. J., O'Connor M. K., Maraganore D. M., Matsumoto J. Y., Stark K. F., Turk M. F., Burnett O. L. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999 Nov;14(6):940–946. doi: 10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  3. Booij J., Habraken J. B., Bergmans P., Tissingh G., Winogrodzka A., Wolters E. C., Janssen A. G., Stoof J. C., van Royen E. A. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998 Nov;39(11):1879–1884. [PubMed] [Google Scholar]
  4. Booij J., Tissingh G., Boer G. J., Speelman J. D., Stoof J. C., Janssen A. G., Wolters E. C., van Royen E. A. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133–140. doi: 10.1136/jnnp.62.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Booij J., Tissingh G., Winogrodzka A., van Royen E. A. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999 Feb;26(2):171–182. doi: 10.1007/s002590050374. [DOI] [PubMed] [Google Scholar]
  6. Brooks D. J. The early diagnosis of Parkinson's disease. Ann Neurol. 1998 Sep;44(3 Suppl 1):S10–S18. doi: 10.1002/ana.410440704. [DOI] [PubMed] [Google Scholar]
  7. Dresel S. H., Kung M. P., Plössl K., Meegalla S. K., Kung H. F. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med. 1998 Jan;25(1):31–39. doi: 10.1007/s002590050191. [DOI] [PubMed] [Google Scholar]
  8. Guttman M., Burkholder J., Kish S. J., Hussey D., Wilson A., DaSilva J., Houle S. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology. 1997 Jun;48(6):1578–1583. doi: 10.1212/wnl.48.6.1578. [DOI] [PubMed] [Google Scholar]
  9. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  10. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Innis R. B., Marek K. L., Sheff K., Zoghbi S., Castronuovo J., Feigin A., Seibyl J. P. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999 May;14(3):436–442. doi: 10.1002/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  12. Ito Y., Fujita M., Shimada S., Watanabe Y., Okada T., Kusuoka H., Tohyama M., Nishimura T. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse. 1999 Mar 1;31(3):178–185. doi: 10.1002/(SICI)1098-2396(19990301)31:3<178::AID-SYN2>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  13. Kaufman M. J., Madras B. K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991 Sep;9(1):43–49. doi: 10.1002/syn.890090107. [DOI] [PubMed] [Google Scholar]
  14. Laruelle M., Baldwin R. M., Malison R. T., Zea-Ponce Y., Zoghbi S. S., al-Tikriti M. S., Sybirska E. H., Zimmermann R. C., Wisniewski G., Neumeyer J. L. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993 Apr;13(4):295–309. doi: 10.1002/syn.890130402. [DOI] [PubMed] [Google Scholar]
  15. Laruelle M., Wallace E., Seibyl J. P., Baldwin R. M., Zea-Ponce Y., Zoghbi S. S., Neumeyer J. L., Charney D. S., Hoffer P. B., Innis R. B. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994 Nov;14(6):982–994. doi: 10.1038/jcbfm.1994.131. [DOI] [PubMed] [Google Scholar]
  16. Lee C. S., Samii A., Sossi V., Ruth T. J., Schulzer M., Holden J. E., Wudel J., Pal P. K., de la Fuente-Fernandez R., Calne D. B. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000 Apr;47(4):493–503. [PubMed] [Google Scholar]
  17. Little K. Y., Gorebig J., Carroll F. I., Mapili J., Meador-Woodruff J. H. Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Brain Res. 1996 Dec 2;742(1-2):313–316. doi: 10.1016/s0006-8993(96)01033-5. [DOI] [PubMed] [Google Scholar]
  18. Morrish P. K., Rakshi J. S., Bailey D. L., Sawle G. V., Brooks D. J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314–319. doi: 10.1136/jnnp.64.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Morrish P. K., Sawle G. V., Brooks D. J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996 Apr;119(Pt 2):585–591. doi: 10.1093/brain/119.2.585. [DOI] [PubMed] [Google Scholar]
  20. Nurmi E., Ruottinen H. M., Kaasinen V., Bergman J., Haaparanta M., Solin O., Rinne J. O. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol. 2000 Jun;47(6):804–808. [PubMed] [Google Scholar]
  21. Pirker Walter, Djamshidian Schiva, Asenbaum Susanne, Gerschlager Willibald, Tribl Gotthard, Hoffmann Martha, Brücke Thomas. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002 Jan;17(1):45–53. doi: 10.1002/mds.1265. [DOI] [PubMed] [Google Scholar]
  22. Seibyl J. P., Marek K. L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., Baldwin R. M., Fussell B., Smith E. O., Charney D. S. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995 Oct;38(4):589–598. doi: 10.1002/ana.410380407. [DOI] [PubMed] [Google Scholar]
  23. Seibyl J. P., Marek K., Sheff K., Baldwin R. M., Zoghbi S., Zea-Ponce Y., Charney D. S., van Dyck C. H., Hoffer P. B., Innis R. B. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997 Sep;38(9):1453–1459. [PubMed] [Google Scholar]
  24. Shaya E. K., Scheffel U., Dannals R. F., Ricaurte G. A., Carroll F. I., Wagner H. N., Jr, Kuhar M. J., Wong D. F. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse. 1992 Feb;10(2):169–172. doi: 10.1002/syn.890100210. [DOI] [PubMed] [Google Scholar]
  25. Tissingh G., Bergmans P., Booij J., Winogrodzka A., Stoof J. C., Wolters E. C., Van Royen E. A. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med. 1997 Sep;24(9):1171–1174. doi: 10.1007/BF01254252. [DOI] [PubMed] [Google Scholar]
  26. Tissingh G., Bergmans P., Booij J., Winogrodzka A., van Royen E. A., Stoof J. C., Wolters E. C. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol. 1998 Jan;245(1):14–20. doi: 10.1007/s004150050168. [DOI] [PubMed] [Google Scholar]
  27. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995 Dec 29;294(2-3):577–583. doi: 10.1016/0014-2999(95)00594-3. [DOI] [PubMed] [Google Scholar]
  28. Vingerhoets F. J., Snow B. J., Lee C. S., Schulzer M., Mak E., Calne D. B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994 Nov;36(5):759–764. doi: 10.1002/ana.410360512. [DOI] [PubMed] [Google Scholar]
  29. Winogrodzka A., Bergmans P., Booij J., van Royen E. A., Janssen A. G., Wolters E. C. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm (Vienna) 2001;108(8-9):1011–1019. doi: 10.1007/s007020170019. [DOI] [PubMed] [Google Scholar]
  30. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990 Jul;13(7):290–296. doi: 10.1016/0166-2236(90)90112-n. [DOI] [PubMed] [Google Scholar]
  31. van Dyck C. H., Seibyl J. P., Malison R. T., Laruelle M., Wallace E., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M., Charney D. S., Hoffer P. B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995 Jul;36(7):1175–1181. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES